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Small trials have been largely overlooked in the early part of the COVID-19 pandemic in favour of
“mega-trials”. As new therapies are urgently needed, phase 2 “proof of concept” studies are crucial as
we move into a new phase of pandemic research. https://bit.ly/3o0K9kl
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Research is the only exit strategy from current coronavirus disease 2019 (COVID-19) restrictions. The
second wave of COVID-19 infections currently affecting most of Europe emphasises that COVID-19, the
disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is likely
to require strict control measures impacting on the daily life of most citizens until either a highly effective
approach to treatment or effective vaccines are in widespread use [1–3].
Management approaches include prophylaxis, treatments that aim to prevent infection, for example in
high risk groups such as healthcare workers [4] or those recently exposed to infected individuals [5], and
treatment of established disease [6]. Among the treatment approaches for established disease, these can be
broadly divided into those that target the virus either, for example, through direct antiviral activity or
interfering with virus access to host cells, and those that target the host immune response. Evidence is
accumulating that much of the morbidity and mortality associated with COVID-19 disease is related to a
dysregulated host immune response and it has been described and clinically observed that COVID-19
often follows a biphasic pattern with an initial viral phase followed in susceptible individuals with a
second “host inflammatory” phase that may be associated with respiratory failure and the development of
acute respiratory distress syndrome [7–9].
It is urgent that effective therapies are found, and a dizzying number of trials have been initiated since the
start of the pandemic. Indeed, the World Health Organization (WHO) database lists more than 2500 trials
worldwide at the last count. Many of these trials are small and several overlap in terms of their
interventions and outcomes. For example, more than 150 unique trials of hydroxychloroquine were
initiated during the early part of the pandemic [10].
The most notable feature of the pandemic has been the impact of the pragmatic “mega-trials” like
RECOVERY and SOLIDARITY [11–13]. These large, open-label trials which are embedded within routine
clinical practice test a number of different interventions simultaneously using streamlined platform designs
incorporating a “standard care” comparator without blinding. Broad inclusion criteria allow large numbers
of patients to be enrolled rapidly and as of 8 November, 2020 RECOVERY had enrolled more than 16000
patients while SOLIDARITY, sponsored by the WHO, recently reported data from 11266 patients in their
initial report of repurposed antiviral drugs [11, 13–15].
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RECOVERY has demonstrated that both hydroxychloroquine and lopinavir–ritonavir are ineffective, and
results of azithromycin, tocilizumab and convalescent plasma arms are expected shortly [11, 14, 15].
SOLIDARITY found no efficacy in terms of the primary outcome of mortality for any of the interventions
tested, namely hydroxychloroquine (rate ratio (RR) 1.19, 95% CI 0.89–1.59), lopinavir–ritonavir (RR 1.00, 95%
CI 0.79–1.25), interferon-β (RR 1.16, 95% CI 0.96–1.39) or remdesivir (RR 0.95, 95% CI 0.81–1.11) [13]. The
sample sizes for hydroxychloroquine (947 versus 906) and lopinavir–ritonavir (1399 versus 1372) were lower
than originally planned as these arms were terminated after RECOVERY found these drugs to be ineffective.
Dexamethasone, which was shown to reduce mortality in hospitalised patients in RECOVERY (RR 0.83,
95% CI 0.75–0.93), particularly in patients requiring mechanical ventilation (RR 0.64, 95%CI 0.51–0.81),
remains at the time of writing the only intervention proven to reduce mortality in COVID-19 [11].
Whether this mortality benefit extends to other steroids has recently been investigated in a prospective
meta-analysis of randomised trials by the WHO REACT working group [16]. They identified trials of
dexamethasone, hydrocortisone and methylprednisolone and reported a reduced mortality for critically ill
patients treated with corticosteroids (OR 0.70, 95% CI 0.48–1.01; p=0.053), albeit nominally not
statistically significant and heavily influenced by the RECOVERY trial [16]. There was little inconsistency,
suggesting an effect that is shared between different corticosteroids.
In the era of “mega-trials” what is the role of smaller proof of concept trials? In this issue of the European
Respiratory Journal, EDALATIFARD et al. [17] report the results of a small, single-blind randomised trial of
intravenous methylprednisolone in severe COVID-19. Patients in the study were randomised 1:1 to 3 days
of 250 mg·day−1 pulsed methylprednisolone or standard care. 34 patients were randomised in each group.
The authors aimed to include patients with evidence of respiratory failure by including patients with
oxygen saturations <90% on air, elevated C-reactive protein and interleukin-6 in the blood, and confirmed
SARS-CoV-2 infection [17].
While a randomised study, the trial had significant limitations including a primary outcome of discharge
or death. This combination of positive and negative outcomes in a single measure is unusual at best and
probably even inappropriate. The authors excluded six patients from the “overall analysis” of the standard
care arm because they received steroids, when usual practice would be to include these patients in the
intention to treat analysis and exclude from a per protocol analysis. Nevertheless, the results of the
meaningful secondary endpoints are striking. Time to clinical improvement was approximately 4.5 days
shorter with methylprednisolone, and mortality was strikingly reduced (5.9% versus 42.9%). The frequency
of serious adverse events was similar between the groups.
The effect estimate in the study, particularly with regard to mortality, is greater than in any of the studies
included in the recent meta-analysis, but with a high degree of uncertainty given the small sample size.
The trial nevertheless supports the conclusions of the REACT meta-analysis that the mortality benefits of
corticosteroids likely extends to these drugs as a class, rather than being limited to dexamethasone [16].
The trial also provides welcome data on the safety of steroids, which were not reported in RECOVERY.
Despite these positive features, the design limitations, a small sample size, the use of hydroxychloroquine,
lopinavir and naproxen as routine background therapy and other design issues mean this study should be
treated with caution.
In the era of “mega-trials” it is important to ask ourselves the question of whether small trials like this
have a role. Should all efforts be focused on recruitment to large scale platforms? My answer would
currently be no. In particular, the negative results from SOLIDARITY illustrated that drugs selected largely
on the basis of theoretical considerations are likely to have a low success rate in large scale studies. The
investment of time, cost and also patient exposure in testing a drug in thousands of patients requires more
than just good in vitro antiviral activity or sound theory. Phase 2 studies to demonstrate preliminary
evidence of efficacy and safety will become more and more important as the pandemic progresses and the
experience with corticosteroids provides a useful argument in favour of this [18]. Most of the smaller
studies conducted to date would point towards a beneficial effect of steroids: in other words, if
dexamethasone or methylprednisolone were a previously unknown agent, testing in a small phase 2 study
would have given sufficient evidence of safety and efficacy to provide confidence regarding incorporating
steroids into “mega-trials” [16]. This provides confidence for doing this more going forward. Studies with
sample sizes ranging from 60 to 300 may provide sufficient proof of concept, and crucially safety, to
prioritise which agents then move into larger scale testing using platforms. Phase 2 platform trials with
standardised protocols and central co-ordination, such as the ACCORD programme in the UK, provide a
means to evaluate early-phase drugs in an efficient way [18].
The counter argument is that bigger is always better and that large trials may identify a signal that small
trials could miss. In this regard, tocilizumab, an interleukin-6 receptor antagonist, will shortly be a
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powerful example. Three randomised trials have recently been published showing no benefit of
tocilizumab on clinical outcomes in hospitalised patients. STONE et al. [19] enrolled 243 patients and found
no significant effect on the primary outcome of intubation or death (hazard ratio 0.83, 95% CI 0.38–1.81;
p=0.64), SALVARANI et al. [20] enrolled 126 patients and showed no effect on clinical worsening (RR 1.05,
95% CI 0.59–1.86), while HERMINE et al. [21] enrolled 131 patients and found no significant effect on any
endpoint. Each had a modest sample size, but none showed convincing efficacy on primary or secondary
endpoints and there are additional unpublished trials also showing lack of efficacy of this intervention.
Despite this, RECOVERY continues to enrol patients into its comparison of tocilizumab versus standard
care. Will the inclusion of 1500–2000 patients allow RECOVERY to find a signal that the small trials miss?
From an evidence-based medicine and strategy perspective moving into the next phase of the pandemic,
this may prove to be a crucial examplar.
Today the message is clear. There have never been more randomised trials globally, and the 2020
SARS-CoV-2 pandemic may come to be regarded as evidence-based medicine’s finest hour if it can deliver
the treatments we need. Corticosteroids are currently the only therapy proven to reduce mortality in
patients hospitalised with COVID-19. Repurposed antiviral treatments have so far proven ineffective in
reducing mortality. New therapies will need to be identified, prioritised and moved into large scale
platform trials in the coming months. We have evidence for steroids, but to generate treatment protocols
that will make a powerful impact on the pandemic we need more, which means enhancing phase 2 trial
capability and feeding the best candidates into large scale platforms. We need evidence based medicine, on
steroids.
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